HBHooman Bakhshandeh

Hooman Bakhshandeh

*This is an algorithmically generated author record based on publicly available information.

Hooman Bakhshandeh has a total of 262 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pregnancy-related outcomes in patients with repaired versus unrepaired coarctation of the aorta: the PEARL retrospective cohort study

    by Mona Yadollahi, Mohammadreza Babaei, Sara Montazeri Namin, Nasrin Ghadakkar, Mahshad Sabri, Soudabeh Shafiee Ardestani, Fahimeh Kashfi, Hooman Bakhshandeh, Mahdi Daliri, Niloufar Samiei, et al.

  • Uncovering Racial Disparities in Lipoprotein(a) Testing Utilization: A Systematic Review and Meta-analysis

    by Amirhossein Ghaseminejad-Raeini, Iman Razeghian, Ali Ghaderi, Amirhossein Shirinezhad, Hooman Bakhshandeh

  • Open Access

    Coated or chewable aspirin and a hybrid air pollution mitigation strategy in patients with atherosclerotic disease: rationale and design of the COATED-AIR randomized trial

    by Behnood Bikdeli, Azita H Talasaz, Hooman Bakhshandeh, Mohammad Sadegh Hassanvand, Hessam Kakavand, Sepehr Jamalkhani, Sina Rashedi, Sara Tayyebi, Mohammadreza Babaei, Erfan Kohansal, et al.

    Aims: Although enteric-coated aspirin is widely used instead of chewable formulations in patients with atherosclerotic cardiovascular disease (ASCVD), its effects on cardiovascular and gastrointestinal outcomes remain uncertain. Separately, air pollution is a driver of cardiovascular risk, yet individual-level interventions have not been tested in outcomes trials. Methods and results: The Coated Or Chewable Aspirin in Patients with Established AThErosclerotic Disease and a Hybrid Strategy to Mitigate the Adverse Effects of AIR Pollution (COATED-AIR) is a randomized trial with a 2 × 2 factorial design planned to address these knowledge gaps. Patients with ASCVD receiving low-dose aspirin are considered for inclusion. Major exclusion criteria consist of being within 72 h of acute/unstable ASCVD or revascularization, triple antithrombotic therapy, active/recent bleeding, life expectancy <1 year, or other barriers or unwillingness for enrolment. Eligible consenting patients are randomized, in a double-blind fashion, to enteric-coated vs. chewable aspirin 81 mg daily and (via factorial randomization) to a hybrid strategy to mitigate the adverse effects of air pollution vs. usual care. The hybrid strategy includes (i) an educational flashcard, (ii) real-time air quality alerts via cellular text messages, and (iii) recommendations to (a) limit outdoor activity or (b) use a KN-95 facemask when outdoors, or (c) increase citrus fruit intake on days with elevated pollution levels. The primary efficacy outcome for the aspirin randomization is a composite of fatal/non-fatal ischaemic stroke, thrombotic/thromboembolic myocardial infarction, and acute limb ischaemia. For the AIR randomization, other forms of cardiovascular death are additionally included in the primary composite outcome. The median planned duration of follow-up is 2 years. Enrolment was completed on 28 January 2026. Clinical follow-up and blinded event adjudications are ongoing. Conclusion: COATED-AIR will determine whether aspirin coating affects its safety or effectiveness, and whether individual-level strategies can mitigate cardiovascular risks from air pollution in patients with ASCVD.


  • Open Access

    CT mitral valve calcium score and immediate outcomes after percutaneous transvenous mitral commissurotomy

    by Pooya Eini, Amir Ghaffari Jolfayi, Ata Firouzi, Farnaz Rafiee, Behnam Ranjbar, Raheleh Kaviani, Mozhgan Parsaee, Mohammad Javad Alemzadeh-Ansari, Hooman Bakhshandeh, Majid Maleki, et al.

  • Feasibility and preliminary effects of high-intensity interval training vs. moderate-intensity continuous training on inflammatory and metabolic biomarkers in type 2 diabetes: a pilot randomized controlled trial

    by Sahar Alizadeh, Mohsen Avandi, Brandon G. Fico, Nahid Mahdieh, Mehdi Hedayati, Camelia Rambod, Hooman Bakhshandeh

    Background Elevated plasma calprotectin, an inflammatory biomarker, is linked to higher cardiovascular risk in type 2 diabetes (T2DM), suggesting lifestyle interventions like exercise may help regulate it. This pilot study evaluated the feasibility of future full-scale trial for comparing the effect of high-intensity interval training (HIIT) vs. moderate-intensity continuous training (MICT) on calprotectin in T2DM patients without cardiovascular disease. Methods This open-label, randomized controlled pilot trial was conducted from December 2018 to March 2019 at the Rajaie Cardiovascular Institute, Tehran, Iran. Participants over 18 years of age with T2DM, an HbA1c between 6.5% and 10%, a BMI between 24 and 35 kg/m2, and stable medication use for at least four weeks before enrollment, were randomly assigned at a 1:1 ratio to HIIT or MICT group for eight weeks. Primary endpoints included recruitment and retention rates, whereas changes in biomarkers after training were secondary endpoints. Results Out of 58 T2DM patients assessed for eligibility, 18 were recruited (9 females, 9 males; mean age: 52 ± 6.0 years; mean BMI: 28.7 ± 3.8 kg/m2), resulting in a recruitment rate of 32%. All participants completed the study, and no adverse events occurred. The calprotectin level decreased in the HIIT group but increased in the MICT group [mean difference (CI95%): 73.4(−337.1, 483.9) vs. −15.4(−553.9, 523.2)]. Conclusions This study demonstrated efficient participant recruitment, complete retention, and safety, indicating that a full-scale trial is feasible. The reduction in calprotectin levels in the HIIT group supports further investigation in the full-scale trial. Trial registration Iranian Registry of Clinical Trials (IRCT), IRCT20181129041797N1, Registered 25 Dec 2018, https://irct.behdasht.gov.ir/trial/35598


  • Unilateral Chronic Thromboembolic Pulmonary Disease: Do Patients Benefit From Thromboendarterectomy? Case Series From Three CTEPH Centres

    by Farid Rashidi, Bedrettin Yıldızeli, Rezayat Parvizi, Serpil Taş, Şehnaz Olgun Yıldızeli, Bülent Mutlu, Eisa Bilehjani, Babak Mahmoudian, Hooman Bakhshandeh, Seyed Ali Mousavi-Aghdas, et al.


  • Open Access

    Effects of Spirulina platensis Supplementation on COVID-19 Severity in Critically Ill Patients: A Randomized Clinical Trial

    by Mahdi Shadnoush, Heitor O. Santos, Monireh Hatami, Mehdi Norouzi, Mohsen Taghavi, Henrique Santa Capita Cerqueira, Mansoore Sadat Mojani- Qomi, Hooman Bakhshandeh, Jamal Rahmani, Zainab Javid, et al.

    Background: Spirulina is a functional food with antioxidant and anti-inflammatory properties. Its anti-inflammatory, antioxidant, antiviral, and immunomodulatory potential may improve certain clinical conditions in patients with coronavirus disease 2019 (COVID-19) in the intensive care unit (ICU). Objectives: This study aimed to investigate the effects of Spirulina supplementation on clinical conditions in critically ill patients with COVID-19. Methods: A double-blind clinical trial randomized patients admitted to an ICU to receive either Spirulina platensis supplementation (5g/day, n = 97) or to a control group (n = 95). The severity of COVID-19 was assessed using the Acute Physiology and Chronic Health Evaluation (APACHE), National Early Warning Score (NEWS) 2, and Sequential Organ Failure Assessment Score (SOFA). The study also evaluated the length of stay in the hospital and ICU, respiratory support at discharge, and 28-day mortality. In the survival analysis, 126 participants were evaluated (58 in the control group and 68 in the Spirulina group). Results: There was no significant difference between the groups in 28-day mortality (HR = 1.07, 95% CI 0.57 - 1.97) or NEWS2 (P = 0.76). However, the SOFA score significantly decreased in the Spirulina group compared to the control group (P = 0.03). The Spirulina group had a shorter ICU length of stay (7.43 ± 3.98 days) compared to the control group (10.00 ± 4.69 days, P = 0.007). The hospital length of stay was also shorter in the Spirulina group compared to the control group (P = 0.001). Conclusions: Spirulina supplementation reduced disease severity (as measured by the SOFA score) and shortened hospital and ICU length of stay in critically ill COVID-19 patients, but it did not reduce mortality.


  • Open Access

    Post-milrinone Administration: Right Ventricular Strain in Right Ventricular Heart Failure-An Observational Echocardiographic Study

    by Maryam Shojaeifard, Soudabeh Behrooj, Hooman Bakhshandeh, Ali Firooz, Mansoureh Niktab, Mohammad Mehdi Beheshtian, Amin Elahifar, Dariush Hooshyar, Hamidreza Hekmat, Yeganeh Dehghani Mohammad Abadi, et al.

    Background: Heart failure significantly affects patient morbidity and mortality, necessitating effective management strategies. Milrinone, a phosphodiesterase-3 inhibitor, has been used to improve cardiac function, but its impact on right ventricular (RV) function requires further investigation. Objectives: This study aimed to evaluate the effect of intravenous milrinone on RV function in patients with RV heart failure, with a specific focus on echocardiographic parameters before and after treatment. Methods: A prospective observational study was conducted at Shahid Rajaei Cardiovascular Medical and Research Center. Twenty-five patients with RV heart failure were included in this study. Each patient received a bolus dose of 50 µg/kg milrinone, followed by an infusion of 0.40 to 0.80 µg/kg/min for 20 minutes. Echocardiographic assessments, including right ventricular strain (RVS), pulmonary artery pressure (PAP), and other relevant parameters, were performed before and after milrinone administration. Results: The study comprised 25 patients (15 males and 10 females). Significant improvements in RV function were observed following milrinone administration. Pulmonary artery pressure decreased significantly from 57.16 ± 31.89 mmHg to 39.86 ± 21.75 mmHg (P < 0.001). Four-chamber RVS improved from -8.75 ± 4.01 to -10.58 ± 4.66 (P = 0.025). Additionally, there was a notable enhancement in free wall RVS. Patients with a history of beta-blocker use exhibited more pronounced improvements in right heart function post-milrinone administration compared to those without such a history. Conclusions: Intravenous milrinone significantly improves RV function in patients with RV heart failure, as evidenced by reductions in PAP and enhancements in RVS. The observed benefits were particularly marked in patients with a history of beta-blocker use, indicating a potential synergistic effect. These findings underscore the importance of tailored therapeutic strategies in managing right heart failure.

  • Open Access

    Review of: "Prevalence and Determinants of Hypertension Among Adults in Urban Bonaberi District of Douala, Cameroon"

    by Hooman Bakhshandeh

    * Please revise the article according to the STROBE statement. * The sampling method should be explained in detail. * Statistical analysis plans and methods may need to be revised. Statistical analysis should begin with univariable analysis, follo...

  • Open Access

    Increased prevalence of thyroid dysfunction in Tehran – HAMRAH study

    by Zahra Ghaemmaghami, Parisa Firoozbakhsh, Delara Gholami, Sajad Khodabandelu, Mohammadreza Baay, Mohammad Javad Alemzadeh-Ansari, Bahram Mohebbi, Zahra Hosseini, Shabnam Boudagh, Hamidreza Pouraliakbar, et al.

    The aim of the current study is to assess the prevalence of different categories of thyroid dysfunction and their associated risk factors among the modern urban population of Tehran, the capital of Iran. The present investigation is a sub-study of the HAMRAH study, a population-based prospective study designed to assess the prevalence of traditional cardiovascular risk factors and their changes through a 10-year follow-up. 2228 (61% female) adults aged between 30 and 75 years old and with no overt cardiovascular diseases were selected through a multistage cluster randomized sampling. Blood levels of thyroid-stimulating hormone (TSH), thyroxin (T4), and triiodothyronine (T3) were measured with the aim of assessing the prevalence of abnormal thyroid function status among the modern urban Iranian population, and in order to report the total prevalence of participants with clinical hypo- or hyperthyroidism, the number of individuals taking thyroid-related drugs were added to the ones with overt thyroid dysfunction. A subgroup analysis was also performed to determine the associated risk factors of thyroid dysfunction. The prevalence of thyroid dysfunction among the total population was 7% (95%CI: 5.9 − 8%) and 0.4% (95% CI: 0.1 − 0.6%) for subclinical and overt hypothyroidism, and 1.6% (95% CI: 1 − 2%) and 0.2% (95% CI: 0 − 0.3%) for subclinical and overt hyperthyroidism, respectively. Clinical thyroid dysfunction was detected in 10.3% of the study population (9.4% had clinical hypo- and 0.9% had clinical hyperthyroidism). In the subgroup analysis, thyroid dysfunction was significantly more prevalent among the female participants (P-value = 0.029). In the current study, the prevalence of different categories of abnormal thyroid status, and also the rate of clinical hypo- and hyperthyroidism was assessed using the data collected from the first phase of the HAMRAH Study. In this study, we detected a higher prevalence of clinical and subclinical hypothyroidism among the Iranian population compared to the previous studies.